Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Cat. Gr:Policy Res. for Health Sys. Trans.- CRPPHE - Pandemic Prep./Health Emerg

University of Toronto

$149,850.00

Building solutions to address drugs shortages in Canada: developing an evidence-based at-risk medicine list

EF 2022-23

Résumé
One in 4 Canadians report being impacted by a drug shortage in the last two years. We have little knowledge of the true impact of drug shortages among Canadian men and women. This is especially important in the current context of a rising number of drug shortages and greater public attention on the topic. In 2019 for example, there were more than 12,000 media reports about drug shortages in Canada, illustrating the importance of this issue to Canadians. This has made this issue a top priority for policymakers in Canada as they scramble to develop policies to solve this growing problem. Importantly, this issue was more heightened during the COVID-19 pandemic as global drug supply chains were tested with rapid surges in demand, in many cases leading to a number of shortages. As policies are being developed they are done so in an environment with scarce information. This gap in evidence is leaves patients, healthcare providers and importantly, policymakers, without the information needed to understand the implications of drug shortages. Our national group of researchers will aim to help tackle this problem by using this grant to develop a national at-risk medicines list levergaing work we have been doing over the last few years. This list will be informed by research on which drugs are at the highest risk and impacted the most Canadians and which drugs have the most clinical risk for patients. We will gather this information and work with a wide group of policymakers, clinicians and researchers to develop a risk assessment tool and then apply that tool to develop a list. This list will be used by decision-makers as they figure out which policies to apply to which drugs. For example, they will explore developing national stockpiles and increase domestic production for the drugs in the highest risk group. This work is supported by many policymakers and is essential immediately to help tackle this growing and important problem.
Programme
Cat. Gr:Policy Res. for Health Sys. Trans.- CRPPHE - Pandemic Prep./Health Emerg
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475138
Name
Tadrous Mina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Policy Research for Health System Transformation
Projecttitle
Building solutions to address drugs shortages in Canada: developing an evidence-based at-risk medicine list
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$149,850
Cihrequipment2
$0
Programname2
Cat. Gr:Policy Res. for Health Sys. Trans.- CRPPHE - Pandemic Prep./Health Emerg
Keyworddelim
Drug Shortages; Formulary; Pharmaceuticals; Supply Chain
Abstract
One in 4 Canadians report being impacted by a drug shortage in the last two years. We have little knowledge of the true impact of drug shortages among Canadian men and women. This is especially important in the current context of a rising number of drug shortages and greater public attention on the topic. In 2019 for example, there were more than 12,000 media reports about drug shortages in Canada, illustrating the importance of this issue to Canadians. This has made this issue a top priority for policymakers in Canada as they scramble to develop policies to solve this growing problem. Importantly, this issue was more heightened during the COVID-19 pandemic as global drug supply chains were tested with rapid surges in demand, in many cases leading to a number of shortages. As policies are being developed they are done so in an environment with scarce information. This gap in evidence is leaves patients, healthcare providers and importantly, policymakers, without the information needed to understand the implications of drug shortages. Our national group of researchers will aim to help tackle this problem by using this grant to develop a national at-risk medicines list levergaing work we have been doing over the last few years. This list will be informed by research on which drugs are at the highest risk and impacted the most Canadians and which drugs have the most clinical risk for patients. We will gather this information and work with a wide group of policymakers, clinicians and researchers to develop a risk assessment tool and then apply that tool to develop a list. This list will be used by decision-makers as they figure out which policies to apply to which drugs. For example, they will explore developing national stockpiles and increase domestic production for the drugs in the highest risk group. This work is supported by many policymakers and is essential immediately to help tackle this growing and important problem.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tadrous, Mina; Mittmann, Nicole; Ahmed, Saad; Fahim, Christine; Gomes, Tara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $149,850~ $0~